Published in PLoS One on March 22, 2013
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Cost-effectiveness of screening for hepatitis C in Canada. CMAJ (2015) 1.16
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. BMJ Open (2016) 0.93
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health (2014) 0.92
Why equal treatment is not always equitable: the impact of existing ethnic health inequalities in cost-effectiveness modeling. Popul Health Metr (2014) 0.89
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health (2014) 0.84
Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med (2015) 0.82
Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol (2015) 0.82
Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques. PLoS One (2015) 0.80
Age-period-cohort analysis of infectious disease mortality in urban-rural China, 1990-2010. Int J Equity Health (2016) 0.78
Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature. Risk Manag Healthc Policy (2015) 0.76
Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus. Open Forum Infect Dis (2015) 0.75
Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Manag Sci (2015) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med (2012) 7.56
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med (2012) 4.29
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2013) 3.65
Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making (2006) 3.62
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol (2011) 3.11
Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2004) 2.57
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
The impact of diagnosis of hepatitis C virus on quality of life. Hepatology (1999) 2.32
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol (1996) 2.24
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med (2007) 1.76
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med (2001) 1.65
Appropriateness of liver biopsy. Can J Gastroenterol (2000) 1.65
Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol (2007) 1.62
All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis (2011) 1.60
Diagnostic tests for hepatitis C. Hepatology (1997) 1.58
Trends in medical spending by age, 1963-2000. Health Aff (Millwood) (2004) 1.42
Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep (2009) 1.39
Health-state utilities in liver disease: a systematic review. Med Decis Making (2008) 1.35
Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med (2011) 1.35
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut (2005) 1.24
Health values of patients with chronic hepatitis C infection. Arch Intern Med (2004) 1.04
Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics. Med Care (2007) 1.03
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One (2011) 0.98
Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat (2006) 0.98
Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health (2010) 0.97
Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med (2000) 0.92
Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin (2004) 0.92
Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int (2008) 0.85
Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat (2011) 0.85
Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol (2010) 0.84
Predictive markers for hepatitis C antibody ELISA specificity in Australian blood donors. Transfus Med (1992) 0.76
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72
Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2013) 3.83
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis (2008) 3.10
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl (2007) 2.61
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res (2011) 2.11
Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation (2010) 2.00
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ (2013) 1.81
An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea. Sleep (2011) 1.80
Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. Ann Emerg Med (2013) 1.74
Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA (2010) 1.71
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine (2007) 1.71
Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis (2016) 1.68
Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2013) 1.68
HIV infection in the elderly. Clin Interv Aging (2008) 1.59
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Ann Intern Med (2015) 1.39
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
Novel targets for antiretroviral therapy: clinical progress to date. Drugs (2009) 1.25
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J Urol (2011) 1.21
Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine (2006) 1.20
Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf (2009) 1.19
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr (2009) 1.19
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18
Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med (2008) 1.15
Role of environmental surveillance in determining the risk of hospital-acquired legionellosis: a national surveillance study with clinical correlations. Infect Control Hosp Epidemiol (2007) 1.12
Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One (2012) 1.11
Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health (2007) 1.10
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making (2007) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Enhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application. BMC Med Inform Decis Mak (2011) 1.04
Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Med (2012) 1.04
HIV testing of at risk patients in a large integrated health care system. J Gen Intern Med (2007) 1.03
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol (2013) 1.03
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Is spinal tuberculosis contagious? Int J Infect Dis (2010) 1.00
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One (2011) 0.98
One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. Int J Infect Dis (2011) 0.97
Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs (2013) 0.97
Diabetes, its treatment, and catastrophic medical spending in 35 developing countries. Diabetes Care (2012) 0.96
Effective detection of the 2009 H1N1 influenza pandemic in U.S. Veterans Affairs medical centers using a national electronic biosurveillance system. PLoS One (2010) 0.96
Determinants of the cost of health services used by veterans with HIV. Med Care (2011) 0.95
Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol (2009) 0.94
The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev (2008) 0.94
Outcomes associated with a cognitive-behavioral chronic pain management program implemented in three public HIV primary care clinics. J Behav Health Serv Res (2012) 0.91
Multi-Country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980-1997. Global Health (2011) 0.91
Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev Recent Clin Trials (2010) 0.91
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist (2013) 0.91
Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr (2009) 0.91
Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med (2014) 0.88
Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection. J Med Virol (2012) 0.87
Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. J Med Virol (2010) 0.87
Mental health services use by children investigated by child welfare agencies. Pediatrics (2012) 0.86
The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2011) 0.86
Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. J Virol (2006) 0.85
Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J Acquir Immune Defic Syndr (2010) 0.85
Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy (2011) 0.84
Frequency of HIV screening in the Veterans Health Administration: implications for early diagnosis of HIV infection. AIDS Educ Prev (2008) 0.83
HIV-1 RNA and viral load. Clin Lab Med (2002) 0.83
Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. Ann Surg (2012) 0.83
Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother (2010) 0.82
Public health practice is not research. Am J Public Health (2014) 0.82
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis (2005) 0.82
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials (2003) 0.82
Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One (2013) 0.82
Proteomic analysis of serum cytokine levels in response to highly active antiretroviral therapy (HAART). J Proteome Res (2005) 0.82
Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Int J Infect Dis (2009) 0.81
The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Qual Life Res (2009) 0.81
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. J Infect Dis (2010) 0.81
Screening with OGTT alone or in combination with the Indian diabetes risk score or genotyping of TCF7L2 to detect undiagnosed type 2 diabetes in Asian Indians. Indian J Med Res (2011) 0.81
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med (2016) 0.80
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. J Acquir Immune Defic Syndr (2013) 0.80
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res (2008) 0.79
Dengue surveillance in Veterans Affairs healthcare facilities, 2007-2010. PLoS Negl Trop Dis (2013) 0.79
Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial. Med Decis Making (2011) 0.79
Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Pharmacotherapy (2009) 0.78
Effect of management strategies and clinical status on costs of care for advanced HIV. Am J Manag Care (2014) 0.78
CD4 counts and mortality in virologically suppressed US veterans. J Int Assoc Provid AIDS Care (2013) 0.78
Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs. Infect Control Hosp Epidemiol (2012) 0.78
Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. MedGenMed (2006) 0.78
Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. AJR Am J Roentgenol (2013) 0.78
Assessing screening policies for childhood obesity. Obesity (Silver Spring) (2012) 0.77
GBV-C viremia and clinical events in advanced HIV infection. J Med Virol (2013) 0.77